Jaffetilchin Investment Partners’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.73M | Buy |
61,688
+11,234
| +22% | +$299K | 0.1% | 137 |
|
|
2025
Q4 | $1.26M | Buy |
50,454
+3,035
| +6% | +$76.5K | 0.07% | 167 |
|
|
2025
Q3 | $1.21M | Buy |
47,419
+19,064
| +67% | +$471K | 0.07% | 167 |
|
|
2025
Q2 | $687K | Sell |
28,355
-65,761
| -70% | -$1.53M | 0.05% | 218 |
|
|
2025
Q1 | $2.38M | Sell |
94,116
-6,648
| -7% | -$174K | 0.17% | 98 |
|
|
2024
Q4 | $2.67M | Buy |
100,764
+69,035
| +218% | +$1.87M | 0.19% | 83 |
|
|
2024
Q3 | $918K | Sell |
31,729
-843
| -3% | -$24.6K | 0.07% | 159 |
|
|
2024
Q2 | $911K | Sell |
32,572
-13,244
| -29% | -$365K | 0.08% | 144 |
|
|
2024
Q1 | $1.27M | Sell |
45,816
-10,015
| -18% | -$278K | 0.11% | 113 |
|
|
2023
Q4 | $1.61M | Sell |
55,831
-439
| -0.8% | -$13.3K | 0.16% | 96 |
|
|
2023
Q3 | $1.87M | Sell |
56,270
-11,348
| -17% | -$401K | 0.21% | 76 |
|
|
2023
Q2 | $2.48M | Buy |
67,618
+12,640
| +23% | +$492K | 0.26% | 64 |
|
|
2023
Q1 | $2.24M | Sell |
54,978
-7,450
| -12% | -$322K | 0.25% | 76 |
|
|
2022
Q4 | $3.2M | Buy |
62,428
+7,138
| +13% | +$342K | 0.39% | 58 |
|
|
2022
Q3 | $2.42M | Buy |
55,290
+1,558
| +3% | +$75.7K | 0.31% | 53 |
|
|
2022
Q2 | $2.82M | Buy |
53,732
+1,828
| +4% | +$93.2K | 0.33% | 56 |
|
|
2022
Q1 | $2.62M | Sell |
51,904
-13,744
| -21% | -$713K | 0.31% | 54 |
|
|
2021
Q4 | $3.88M | Buy |
65,648
+2,286
| +4% | +$113K | 0.37% | 53 |
|
|
2021
Q3 | $2.73M | Sell |
63,362
-55,961
| -47% | -$2.48M | 0.29% | 63 |
|
|
2021
Q2 | $4.53M | Buy |
119,323
+58,040
| +95% | +$2.26M | 0.31% | 59 |
|
|
2021
Q1 | $2.22M | Sell |
61,283
-1,514
| -2% | -$53.8K | 0.26% | 71 |
|
|
2020
Q4 | $2.31M | Buy |
62,797
+2,342
| +4% | +$85.9K | 0.33% | 49 |
|
|
2020
Q3 | $2.1M | Buy |
60,455
+22,396
| +59% | +$785K | 0.39% | 46 |
|
|
2020
Q2 | $1.18M | Buy |
38,059
+10,973
| +41% | +$373K | 0.26% | 59 |
|
|
2020
Q1 | $839K | Buy |
27,086
+1,978
| +8% | +$67.4K | 0.3% | 49 |
|
|
2019
Q4 | $933K | Buy |
25,108
+905
| +4% | +$32.2K | 0.2% | 73 |
|
|
2019
Q3 | $825K | Sell |
24,203
-538
| -2% | -$19.6K | 0.2% | 78 |
|
|
2019
Q2 | $1.02M | Buy |
+24,741
| New | +$982K | 0.24% | 70 |
|
|
2018
Q1 | – | Sell |
-7,670
| Closed | -$264K | – | 340 |
|
|
2017
Q4 | $264K | Buy |
+7,670
| New | +$262K | 0.09% | 194 |
|
|
2017
Q2 | – | Sell |
-8,096
| Closed | -$263K | – | 276 |
|
|
2017
Q1 | $263K | Sell |
8,096
-1,133
| -12% | -$35.7K | 0.07% | 220 |
|
|
2016
Q4 | $284K | Buy |
9,229
+55
| +0.6% | +$1.68K | 0.08% | 195 |
|
|
2016
Q3 | $295K | Sell |
9,174
-174
| -2% | -$5.82K | 0.09% | 173 |
|
|
2016
Q2 | $312K | Buy |
+9,348
| New | +$298K | 0.09% | 175 |
|
Other funds holding PFE
VCM
VPM
Jaffetilchin Investment Partners's PFE Position: Q1 2026 in Review
Jaffetilchin Investment Partners increased its Pfizer (PFE) stake by 22% in Q1 2026, buying an estimated $299K and bringing the position to 61,688 shares worth $1.73M. The position accounts for 0.1% of the portfolio, ranked #137.
Jaffetilchin Investment Partners first reported a position in PFE in Q2 2016 and has held it in 33 quarters since. The position peaked at $4.53M in Q2 2021. 2,938 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- Jaffetilchin Investment Partners held 61,688 shares of Pfizer worth $1.73M as of Q1 2026.
- Jaffetilchin Investment Partners bought 11,234 Pfizer shares in Q1 2026, an estimated $299K.
- Pfizer made up 0.1% of Jaffetilchin Investment Partners's portfolio in Q1 2026, its #137 holding.
- Jaffetilchin Investment Partners first reported a position in Pfizer in Q2 2016 and has held it in 33 quarters since.
- Jaffetilchin Investment Partners's Pfizer position peaked at $4.53M in Q2 2021.
- 2,938 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on Jaffetilchin Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.